Mangoceuticals, Inc. (NASDAQ:MGRX – Get Rating) CEO Jacob D. Cohen purchased 275,000 shares of the firm's stock in a transaction dated Monday, April 10th. The shares were acquired at an average cost of $1.00 per share, with a total value of $275,000.00. Following the completion of the purchase, the chief executive officer now directly owns 8,275,000 shares in the company, valued at $8,275,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mangoceuticals Stock Performance

NASDAQ:MGRX opened at $1.03 on Wednesday. Mangoceuticals, Inc. has a 1-year low of $0.86 and a 1-year high of $4.37.

Mangoceuticals Company Profile

(Get Rating)

Mangoceuticals Inc is involved in developing, marketing and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction drug branded `Mango`. Mangoceuticals Inc is based in DALLAS, TX.

See Also

• Get a free copy of the StockNews.com research report on Mangoceuticals (MGRX)
• Do Bank Stocks Go Up When Interest Rates Rise?
• How to Invest in Vertical Farming Stocks
• Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
• Ecolab: Slow And Steady Wins The Race
• MGM's Hot Hand Is All In For A Rally, After This Small Break

Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.